Grünenthal Spain company information, Employees & Contact Information

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal PR Newswire

Grünenthal goes for Cialis in latest targeted acquisition The Pharma Letter

Grünenthal delivers exceptional financial results in 2024 The Pharma Letter

Latham & Watkins Advises Grünenthal on €500 Million Bond Latham & Watkins LLP

Grünenthal acquires Valinor Pharma Pharmaceutical Technology

Grünenthal designates $87M to update plants in Ecuador and Chile Fierce Pharma

Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy Labiotech.eu

Dr. Frances Kelsey vs. Chemie Grünenthal Global Biodefense

AZ sells rights to statin med Crestor to Grünenthal PharmaTimes

Grünenthal identifies new Nav1.8 blockers for pain BioWorld MedTech

Mesoblast and Grunenthal Partner on Lower Back Pain Cell Therapy Investing News Network

Sanofi diabetes research chief takes CSO post at Grünenthal Fierce Biotech

Grünenthal continues US growth push with $250M acquisition of Valinor Pharma Fierce Pharma

Grünenthal announces pricing of 500 million-euro bond The Pharma Letter

AstraZeneca signs $922m licensing deal with Grünenthal Pharmaceutical Technology

Kyowa Kirin offloads mature drugs to Grünenthal amid 'challenging business environment' Fierce Pharma

Grünenthal's transformation: CEO Gabriel Baertschi about what's ahead for the global leader in pain management Fierce Pharma

Jan Adams to replace Janneke van der Kamp as Grünenthal CCO The Pharma Letter

In $500M deal, Bayer offloads testosterone deficiency drug Nebido to Grünenthal Fierce Pharma

AstraZeneca hands European Crestor rights to old customer Grünenthal for $350M Fierce Pharma

Duchenne Muscular Dystrophy Drug to Be Developed by Grünenthal and Akashi Therapeutics Muscular Dystrophy News

Grünenthal Acquires Partial Rights to Nexium, Vimovo from AstraZeneca for Up-to-$922M Genetic Engineering and Biotechnology News

Grünenthal and Freshfields win injunction against Teva testosterone drug JUVE Patent

AZ jilts gout med Zurampic with $230M rights sale to Grunenthal Fierce Pharma

Grünenthal increases loan to €600m GlobalCapital

New Grunenthal CEO Forges Ahead with Treatment for Complex Regional Pain Syndrome BioSpace

Grunenthal insists crush-proof tablet works after Endo pulls Opana sNDA Fierce Pharma

AstraZeneca Divests Two Drugs to Grünenthal in $90 Million Deal BioSpace

Scientists quit back pain campaign over links to opioid giant Grünenthal The Times

Former boss of thalidomide maker Grünenthal apologises to victims The Times

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia Via Ritzau

AZ’s Gabriel Baertschi joins Grünenthal as CEO PMLiVE

Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors Via Ritzau

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik® Via Ritzau

Maren Thurow starts as new Head Global Communications at Grünenthal | Grünenthal Group Via Ritzau

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer Via Ritzau

Grünenthal Group: Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer NTB Kommunikasjon

Grunenthal to market MSD’s pain drug PMLiVE

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients Via Ritzau

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million Via Ritzau

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain Via Ritzau

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer | news aktuell GmbH NTB Kommunikasjon

Grünenthal’s Harald Stock joins OvaScience board PMLiVE

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients STT Info

German Grünenthal Group acquires Adhesys Medical for its surgical sealant technology Tech.eu

Janneke van der Kamp, nueva Chief Commercial Officer de Grünenthal Forbes España

Grünenthal closes deal with AstraZeneca Irish Medical Times